Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability: 2022-2024

Historic Non-Current Deferred Tax Liability for Sunshine Biopharma (SBFM) over the last 2 years, with Dec 2024 value amounting to $389,513.

  • Sunshine Biopharma's Non-Current Deferred Tax Liability rose 72.74% to $389,513 in Q4 2024 from the same period last year, while for Dec 2024 it was $389,513, marking a year-over-year increase of 72.74%. This contributed to the annual value of $389,513 for FY2024, which is 72.74% up from last year.
  • As of Q4 2024, Sunshine Biopharma's Non-Current Deferred Tax Liability stood at $389,513, which was up 699.35% from $48,729 recorded in Q3 2024.
  • In the past 5 years, Sunshine Biopharma's Non-Current Deferred Tax Liability registered a high of $389,513 during Q4 2024, and its lowest value of $43,032 during Q4 2022.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $48,729 (2024), whereas its average is $103,702.
  • Data for Sunshine Biopharma's Non-Current Deferred Tax Liability shows a peak YoY surged of 424.01% (in 2023) over the last 5 years.
  • Sunshine Biopharma's Non-Current Deferred Tax Liability (Quarterly) stood at $43,032 in 2022, then skyrocketed by 424.01% to $225,493 in 2023, then spiked by 72.74% to $389,513 in 2024.
  • Its Non-Current Deferred Tax Liability was $389,513 in Q4 2024, compared to $48,729 in Q3 2024 and $48,729 in Q2 2024.